

**Adult CIRB - Early Phase Emphasis Meeting Agenda**

**December 17, 2024**

---

**I Amendment**

**10449**, A Phase 1 Study of ZEN003694 in Combination with Binimetinib in Solid Tumors with RAS Pathway Alterations and Triple Negative Breast Cancer (Version Date 10/29/24)

---

**II Continuing Review**

**10492**, Phase 1/1b Study of AKT Inhibitor Ipatasertib with Chemoradiation for Locally Advanced Head and Neck Cancer (Version Date 08/14/24)

---

**III Continuing Review**

**10499**, Phase Ib/II study of ZEN003694 and entinostat in advanced and refractory solid tumors and lymphomas (Version Date 08/21/24)

---

**IV Continuing Review**

**10563**, A Phase 1 Study of Peposertib (M3814) and Low-Dose Liposomal Doxorubicin in Patients with Metastatic Leiomyosarcoma and Other Soft Tissue Sarcomas (Version Date 10/03/24)

---

**V Continuing Review**

**10597**, A Phase 1 Study of APG-1252 (pelcitoclax) and cobimetinib in recurrent ovarian and endometrial cancers (Version Date 07/02/24)

---